InspireMD (NSPR) Announces Publication of Positive CGuard EPS Data
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
InspireMD, Inc. (NYSE: NSPR) announced the online publication of positive clinical data in a new independent study performed by Prof. Christian Wissgott, M.D., entitled "Clinical Results and Mechanical Properties of the Carotid CGuard™ Double-Layered Embolic Prevention Stent," which evaluated the Company's CGuard™ EPS in patients with symptomatic or high-grade asymptomatic internal carotid artery (ICA) stenosis. The study, published in the Journal of Endovascular Therapy online-ahead-of-print, is available digitally on the journal's OnlineFirst website section. The OnlineFirst section also includes an accompanying editorial written by Prof. Piotr Musialek, M.D., entitled "Carotid Artery Revascularization for Stroke Prevention: A New Era," which underscores the use of CGuard™ EPS as a novel approach to potentially reducing the risk of stroke by avoiding the risks associated with conventional carotid stenting.
Prof. Christian Wissgott, M.D., Assistant Director at Westkustenklinikum, Heide, Germany, independently evaluated CGuard™ properties against other carotid stents and conducted a study in 30 consecutive patients with Internal Carotid Artery Stenosis (ICA) disease. The average stenosis of the treated arteries was 84% with a mean lesion length of 17 mm. The majority of the patients (83%) had symptomatic disease. Patients were followed for six months post-procedure and were assessed using a number of variables, including stroke, change in modified Rankin Scale (mRS), CGuard™ EPS patency, and new ipsilateral lesions as measured by DW-MRI. Key findings from the six month study included:
100% success in implanting the CGuard™ EPS; No peri- or post-procedural complications; No deaths, major adverse events, minor or major strokes, or new neurologic symptoms during the six months following the procedure; Modified Rankin Scale improved for the symptomatic patients from 1.56 prior to the procedure to 0 afterwards; All vessels treated with the CGuard™ system remained patent (open) at six months; and DW-MRI performed in 19 of 30 patients found no new ipsilateral lesions after 30 days and after six months compared with the baseline DW-MRI studies.
Additionally, based on engineering evaluations, the study concluded that the CGuard™ EPS provides a high radial force and strong support in stenotic lesions, and its structure, in contrast to some other stents, adapted well to changes in vessel diameter and direction. The MicroNet™ mesh of the CGuard™ did not cause any changes to specific mechanical parameters of the underlying stent.
"The novel construction of the CGuard™ EPS prevented post-procedural embolic events in this series of patients undergoing routine carotid artery stenting," said Prof. Wissgott. "The CGuard™ EPS is easy and safe to implant because it more readily adapts to the shape and diameter of the vessel wall versus other carotid artery stents. Importantly, none of the patients in this series experienced any complications or strokes as a result of the procedure or in the following six months. Consequently, I believe that the CGuard™ EPS is an important new treatment option for both symptomatic and asymptomatic carotid artery stenosis patients."
Key points highlighted in the companion editorial from Piotr Musialek, M.D., DPhil, FESC, Prof. in the Jagiellonian University Department of Cardiac & Vascular Diseases include:
85% of strokes occur without warning signs, raising questions about the validity of "watchful waiting" in patients with asymptomatic carotid artery stenosis; Novel stent technology ensures viability of endovascular approaches to carotid revascularization in both primary and secondary stroke prevention; Consistent clinical evidence is accumulating that demonstrates that mesh covered stents, with InspireMD's CGuard™ EPS in particular, prevent post-procedural embolic events; and Data in Wissgott et al is consistent with the positive outcomes reported in all other clinical trials of CGuard™.
"Given the risks associated with prior carotid stent options to date, many physicians prefer to treat their asymptomatic patients with medication-only rather than medication plus interventional plaque pacification," said Prof. Musialek. He continued, "The growing body of data for the CGuard™ EPS demonstrates that this novel system may have a much lower risk of peri- or post-procedural complications and embolic events. Prof. Wissgott's study and the results of the CARENET and PARADIGM 101 studies demonstrate that CGuard™ EPS may help to reduce the risk of stroke for asymptomatic patients and provide them with improved long-term cerebrovascular outcomes. There is little to no doubt today that a new carotid revascularization era has arrived."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- InspireMD (NSPR) Names New CCO
- Myriad Genetics (MYGN) Announces Positive Results from BRACAnalysis CDx Test
- XL Group (XL) Announces Senior Management Changes Related to Realigned P&C Operating Model
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!